02:43 , Jun 1, 2019 |  BioCentury  |  Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

While strong progress in CAR T therapies will again feature at this year’s ASCO meeting, bispecific antibodies are having a moment -- making more inroads into solid tumors than CAR Ts and branching out via...
23:23 , Feb 20, 2019 |  BC Innovations  |  Distillery Therapeutics

Endocrine/metabolic

INDICATION: Diabetes Mouse studies suggest agonizing GITR could help treat insulin resistance. In genetic and high-fat diet-induced mouse models of insulin resistance, a GITR agonist mAb increased glucose tolerance and insulin sensitivity and decreased fasting...
13:31 , Feb 13, 2019 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Acute lymphoblastic leukemia (ALL); melanoma Mouse studies suggest inhibiting CD95 could help enhance the efficacy of adoptive T cell therapies for melanoma and ALL. In a mouse model of melanoma, adoptive transfer of T...
21:44 , Feb 12, 2019 |  BC Extra  |  Company News

Management tracks: Sanofi, Alexion, bluebird

Sanofi (Euronext:SAN; NASDAQ:SNY) said Ameet Nathwani will become the pharma's first chief digital officer in addition to his current role of EVP, CMO. Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) said SVP, Business Development and Corporate Strategy Aradhana...
15:18 , Apr 13, 2018 |  BC Week In Review  |  Clinical News

China FDA approves IND for Canbridge's GBM candidate

Canbridge Life Sciences Ltd. (Beijing, China) said China FDA approved an IND to begin a Phase II/III trial of asunercept (APG101, CAN-008) to treat glioblastoma multiforme (GBM). A spokesperson told BioCentury that Canbridge plans to...
01:21 , Jan 12, 2018 |  BC Innovations  |  Translation in Brief

In the twenties

A Cancer Cell study from University of Southampton and Celldex Therapeutics Inc. (NASDAQ:CLDX) researchers suggests combining CD27 agonists with tumor-targeting mAbs could help myeloid cells attack a broad array of cancers. The partners are testing...
23:17 , Sep 29, 2017 |  BioCentury  |  Strategy

Bridge to innovation

While Zai Lab Ltd. has joined the ranks of Chinese biotechs making a splash on NASDAQ, less noticed may be the first wave of China-based players moving into Boston to jump-start their push into novel...
23:16 , Jul 13, 2017 |  BC Week In Review  |  Clinical News

Apogenix's asunercept receives PRIME designation for glioblastoma

In late May, Apogenix AG (Heidelberg, Germany) said EMA granted PRIority MEdicines (PRIME) designation to asunercept (APG101, CAN-008) to treat glioblastoma. The designation is based on data from a Phase II trial in which asunercept...
19:49 , May 26, 2017 |  BC Week In Review  |  Clinical News

AbbVie starts Phase I for TRAIL-receptor agonist in cancer

Apogenix AG (Heidelberg, Germany) said partner AbbVie Inc. (NYSE:ABBV) began a Phase I trial to evaluate ABBV-621 (APG880) in 92 patients with relapsed or refractory solid tumors, non-Hodgkin’s lymphoma (NHL) or acute myelogenous leukemia (AML)....
22:03 , May 23, 2017 |  BC Extra  |  Financial News

Lapam leads Canbridge's $25M series B

Canbridge Life Sciences Ltd. (Beijing, China) raised $25 million in a series B led by Lapam Capital. Also participating were Qiming Venture Partners, Yuanming Capital, Yanyuan Capital, Biossom Investment Management and WuXi AppTec Co. Ltd....